The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer.
暂无分享,去创建一个
J. Forbes | R. Gelber | B. Gusterson | A. Goldhirsch | J. Collins | A. Coates | B. Thürlimann | D. Crivellari | K. Price | M. Castiglione‐Gertsch | J. Lindtner | M. Fey | A. Wallgren | P. Karlsson | B. Cole | E. Murray | S. Holmberg
[1] C. Grau,et al. Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] R. Collins,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[3] R. Gelber,et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] J. Kao,et al. Does the number of lymph nodes examined in patients with lymph node‐negative breast carcinoma have prognostic significance? , 2005, Cancer.
[5] A. Taghian,et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Satagopan,et al. A note on competing risks in survival data analysis , 2004, British Journal of Cancer.
[7] M. Bonetti,et al. Patterns of treatment effects in subsets of patients in clinical trials. , 2004, Biostatistics.
[8] M. Bonetti,et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. , 2003, Journal of the National Cancer Institute.
[9] H. Putter,et al. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. , 2003, European journal of cancer.
[10] P. Catalano,et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Forbes,et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. , 2003, Journal of Clinical Oncology.
[12] E. Yıldırım,et al. The prognostic significance of total lymph node number in patients with axillary lymph node-negative breast cancer. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[13] G. Storme,et al. Effect of the number of uninvolved nodes on survival in early breast cancer. , 2003, Oncology reports.
[14] M. Bonetti,et al. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. , 2002, Journal of the National Cancer Institute.
[15] L. Holmberg,et al. Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[16] J. Peterse,et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Edge,et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] B. Nordenskjöld,et al. Indicators of loco-regional recurrence in breast cancer. The South East Swedish Breast Cancer Group. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[19] R. Gelber,et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? , 2000, The Lancet.
[20] R. Prescott,et al. Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial , 2000, The British journal of surgery.
[21] R. Gray,et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[23] B. Rasmussen,et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial , 1999, The Lancet.
[24] R. Gelber,et al. Radiotherapy and chemotherapy in high-risk breast cancer. , 1998, The New England journal of medicine.
[25] K. Zedeler,et al. Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy , 1997 .
[26] J. Forbes,et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] A. Goldhirsch,et al. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. , 1985, Human pathology.
[28] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[29] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[30] I. Fentiman,et al. A high number of tumor free axillary lymph nodes from patients with lymph node negative breast carcinoma is associated with poor outcome , 2002, Cancer.
[31] M. Zelen,et al. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Green,et al. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] M. Zelen,et al. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.